Vitiligo and Pigmentation Institute of Southern California

Recent papers from Vitiligo and Pigmentation Institute of Southern California

1. Beyond Pigment Loss: Three Therapeutic Objectives in VitiligoInternational Journal of Dermatology · 2026
2. Pharmacological solutions for vitiligo: emerging role of Janus kinase inhibitorsExpert Opinion on Pharmacotherapy · 2026
3. Definition of Severity and Relapse for VitiligoJAMA Dermatology · 2026
4. Evaluation of Tinted Sunscreens Protection Against Blue Light Using Transmittance Spectroscopy In Vitro TechniquePhotodermatology Photoimmunology & Photomedicine · 2026
5. The Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE StudyDermatology and Therapy · 2026
6. Defining Important Aspects of Repigmentation in Vitiligo: Insights From Patients' PerspectivesPigment Cell & Melanoma Research · 2026
7. Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publicationTherapeutic Advances in Chronic Disease · 2025
8. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin TonesJAMA Dermatology · 2025
9. Guselkumab for Moderate to Severe Psoriasis Across All Skin TonesJAMA Dermatology · 2025
10. Mental Health and Psychosocial Burden Among Patients with Skin of Color Living with Vitiligo: Findings from the Global VALIANT StudyDermatology and Therapy · 2025
11. Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 StudiesDermatology and Therapy · 2025
12. Unraveling genetic predisposition and oxidative stress in vitiligo development and the role of artificial intelligence (AI) in diagnosis and managementJournal of Medical Biochemistry · 2025
13. Improving Diversity in a Novel Psoriasis StudyJAMA Dermatology · 2024
14. Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 yearsSkin Health and Disease · 2024
15. Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeksJournal of the European Academy of Dermatology and Venereology · 2024
16. Evaluation of an advanced antioxidant and double‐conjugated retinoid/AHA cream in participants with FST IV–VJournal of Cosmetic Dermatology · 2024
17. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithmJournal of the European Academy of Dermatology and Venereology · 2023
18. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendationsJournal of the European Academy of Dermatology and Venereology · 2023
19. Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib CreamJID Innovations · 2023
20. Mental Health and Psychosocial Quality-of-Life Burden Among Patients With VitiligoJAMA Dermatology · 2023